All reactions were performed in duplicate to confirm reproducibility. All MoAbs were validated with HUV-EC-C (ATCC no. CRL-1730, http://www.selleckchem.com/products/LBH-589.html Manassas, VA) cells cultivated in 199/EBS medium complemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/mL streptomycin in our laboratory. We selected all living cells in a side scatter (SSC)/CD45 plot (R1). We then chose and delimited the region correspondent to the CD45 negative and low SSC (R2). Subsequently, we looked for CD146, CD34, CD62e and CD133 expression in other 2D fluorescence plots from R2 (Figure 1). ECPs were considered as CD45−/dim/CD146+/−/CD133+/CD62e− and MECs as CD45−/dim/CD146+/CD62e+/−/CD133−8 and 9.

The percentage of CECs was determined as a percentage of the total events after exclusion of debris. The absolute count of the cells was then calculated by multiplying the %EPCs or %MCEs obtained by flow cytometry by absolute white cell count provided by the hematology analyzer. Statistical analysis was performed with the BioEstat 4.0 software using the Mann-Whitney nonparametric test for a two-tailed probability with alpha level significance of 5%. There was no statistical difference in median age between asymptomatic HTLV-I carriers and healthy controls. The median age of the 27 HTLV-I carriers enrolled in this study was

45 years (range: 27–65 years); 11 (41%) were male and 16 (59%) were female. The median age of the 30 healthy control subjects was 45.5 years (range: 20–63 years); 11 (36.6%)

were male and 19 (63.4%) were female. The median leukocyte Selleckchem Romidepsin count of the HTLV-I carriers was 6.8 × 109/L (4.0 × 109/L to 14 × 109/L) and 6.2 × 109/L (4.0 × 109/L to 10.6 × 109/L) in the control group. No significant statistical difference was found between the results obtained in duplicate reactions. We found that the number of EPCs was significantly higher in HTLV-I carriers (median 0.8288 cells/μL, range: 0.0920–3.3176 cells/μL) as compared to control group (median 0.4905 cells/μL, range: 0.0000–1.5660 cells/μL) (p = 0.035) ( Table 1). The median of the MECs in the HTLV-I carriers was 0.6380 cells/μL (range: 0.0473–5.7618 cells/μL) and 0.4950 cells/μL (range: 0.0000−4.0896 GPX6 cells/μL) in the control group (p = 0.697). Here we demonstrated an increase of EPCs in peripheral blood of HTLV-I carriers in comparison with healthy individuals. To our knowledge, the angiogenesis features in asymptomatic HTLV-I carriers were not previously studied, and it was studied only in patients with cancer, where there were high numbers of EPCs and MECs 8, 10 and 11. However, it may be very important to study the number of EPCs in ATLL patients to confirm our results. In this trial we used flow cytometry to detect EPCs and MECs, although the exact phenotype of these cells remains controversial (12). However, our data suggest that recruitment of EPCs may play a role in angiogenesis in HTLV-I carriers.